Healthcare Roundup – CytoDyn to file marketing application for leronlimab, Takeda submits supplemental application for Cabometyx Life Science
Developing New Treatments with a Proprietary Cell-Based Therapy Platform | Lineage Cell Therapeutics, Inc. (NYSE American: LCTX) Life Science
Healthcare Roundup – Lilly ends COVID-19 antibody trial, Moderna inks COVID-19 vaccine supply deal in Qatar Life Science
Healthcare Roundup – FDA getting cold feet on EUA nod for COVID-19 vaccines, AstraZeneca COVID-19 deal allows 20% gross profit Life Science
Healthcare Roundup – FDA OKs Gilead’s remdesivir, Moderna completes enrollment for Phase 3 study of Covid-19 vaccine Life Science
Healthcare Roundup – J&J’s daratumumab extends survival in first-line multiple myeloma, Death reported in Brazil study of AstraZeneca COVID-19 vaccine Life Science
Healthcare Roundup – CytoDyn study of leronlimab for COVID-19 passes first interim tollgate, Novavax to present COVID-19 vaccine data Life Science
Healthcare Roundup – CVS looks to hire another 15,000 employees, Pfizer and Moderna pivotal studies on COVID-19 vaccines near enrollment targets Life Science
Healthcare Roundup – Sinovac’s COVID-19 vaccine offered by Chinese city for emergency use, CytoDyn to discuss DSMC’s review of interim analysis in COVID-19 Life Science
Healthcare Roundup – Remdesivir has little effect on mortality, Gilead Science lands WHO distinction for remdesivir Life Science
Boosted by Hong Kong Capital, will TAAT’s stock take off? | Taat Lifestyle & Wellness Ltd. Consumer Goods, Life Science
Healthcare Roundup – Trump administration expands collaboration with AstraZeneca on COVID-19 antibody drug, Moderna makes headway in bringing COVID vaccine to European market Life Science
Healthcare Roundup – First case of COVID-19 reinfection confirmed in the U.S.; Relief/NeuroRx reports encouraging Aviptadil data Life Science
Healthcare Roundup – Lilly/Innovent rituximab injection OK’d in China; BioNTech, Pfizer announce rolling submission for COVID-19 vaccine candidate Life Science
Healthcare Roundup – Late-stage study of Emergent Bio’s COVID-19 plasma, Lilly’s baricitinib shows incremental benefit Life Science
